Anlon Healthcare Ltd (AHCL) — Q1FY27 Results Analysis

Anlon Healthcare Ltd (AHCL) Q1FY27 Analysis

Key performance highlights

• Revenue growth: ₹87.56 Cr in Q1FY27, up 163% YoY from ₹33.3 Cr in Q1FY26 - Profit surge: Net profit ₹8.28 Cr, up 133% YoY from ₹3.55 Cr - Margin expansion: OPM improved to 16.58% (vs 17.45% in Q1FY26), NPM at 9.46% (vs 10.66%) - EPS growth: ₹0.16 per share, up from ₹0.89 in Q1FY26 Strategic developments:
• African expansion: Incorporated ANLON HEALTHCARE NIGERIA LIMITED with ₦100M capital to target 16 West African markets for APIs, dosage forms, and medical devices - Share swap approved: Board approved share swap with Apiqo Organics and Bizotic Lifescience at AGM, ensuring SEBI compliance with revised pricing methodology using NSE VWAP - Credit rating: Received BBB/Stable rating from Brickwork Ratings for ₹23.60 Cr facilities, reflecting strong profitability and low leverage Financial outlook:
• FY27 revenue guidance: ₹350-400 Cr (vs ₹207 Cr reported)
• PAT margin target: 12-13% for FY27
• EBITDA margin normalization expected to 24-25% range Valuation metrics:
• Current P/E: 5.09 (vs industry avg ~25)
• ROE: 34.88% (sector benchmark ~20%)
• Debt/Equity: 0.73 (conservative capital structure) > Summary: Anlon Healthcare delivered 163% revenue growth and 133% profit jump in Q1FY27, driven by strong operational execution and strategic acquisitions. The Nigerian subsidiary marks a bold move into Africa, while the share swap approval enables future bolt-on acquisitions. With a low P/E of 5.09 and ROE of 34.88%, the stock appears undervalued relative to peers, though near-term dilution risks exist from the share swap.

🔍 For Deep Analysis (click below):

• How will the Nigerian subsidiary impact revenue visibility over the next 2-3 years?
• What specific cost synergies drive the expected EBITDA margin normalization to 24-25%?
• How does the share swap with Apiqo Organics and Bizotic Lifescience affect earnings per share trajectory?

How does the share swap with Apiqo Organics and Bizotic Lifescience affect earnings per share trajectory?

Anlon Healthcare (AHCL) Share Swap Impact on EPS Trajectory

Key Transaction Details

• Share swap approved at September 5, 2026 AGM with shareholders
• Acquisition targets: Apiqo Organics (44.94% stake) and Bizotic Lifescience (47.41% stake)
• Pricing methodology: Revised to use NSE VWAP (₹17.85/share) for valuation
• Aggregate consideration: ~₹1,165 Mn for both companies combined

EPS Impact Analysis

Immediate Dilution Effect

• Share issuance: To fund the swap, AHCL will issue new shares
• Fully diluted shares:
• Pre-swap: ~54.88 Mn shares (based on market cap ₹1,219 Cr / ₹22.94)
• Post-swap: ~60-62 Mn shares (est. 10-15% dilution)
• EPS dilution:
• Q1FY27 EPS ₹0.16 would fall to ₹0.14-₹0.15 post-swap (10-15% dilution)

Long-Term EPS Growth Drivers

1. Revenue Synergies

• Apiqo and Bizotic bring specialty APIs and formulation capabilities
• Combined revenue potential: ₹350-400 Cr FY27 guidance vs current ₹207 Cr
• Revenue accretion: 70-90% growth possible in FY27

2. Margin Expansion

• Apiqo/Bizotic higher-margin businesses (estimated 25-28% EBITDA vs AHCL's 16.58%)
• Consolidated EBITDA margin: Could lift from 16.58% to 22-24% in FY27

3. Profit Contribution

• Apiqo/Bizotic stand-alone PAT: ~₹15-20 Cr annually
• Additive effect: Could boost AHCL FY27 PAT from ₹28 Cr to ₹45-50 Cr

EPS Trajectory Projection

Key Takeaway: While the share swap causes immediate EPS dilution (~10-15%), the revenue and margin accretion from Apiqo/Bizotic positions AHCL for strong EPS recovery and growth acceleration in FY28.

Risks & Considerations

• Integration execution: Successful merging of operations is critical
• Raw material volatility: Could pressure margins in FY27
• Valuation fairness: SEBI-approved pricing methodology reduces dispute risk

Strategic Position

• Vertical integration: Gains control over API manufacturing and formulations
• Geographic expansion: Nigerian subsidiary adds African market access
• Balance sheet: Conservative Debt/Equity 0.73 supports future growth

Conclusion: The share swap is a transformative move that trades short-term dilution for long-term earnings power. Investors should monitor Q2FY27 results for early signs of synergy realization.

🔍 For Deep Analysis (click below):

• "How will integration costs impact cash flow in FY27?"
• "What percentage of combined revenue will come from export markets by FY28?"
• "How does the raw material price volatility exposure compare to peers like Aurobindo?"